2-(2-乙基苯基)乙腈 | 74533-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-乙基苯基)乙腈
• 英文名称: 2-(2-ethylphenyl)acetonitrile
• CAS: 74533-20-3
• 化学式: C₁₀H₁₁N
• mdl: MFCD09923659
• 分子量: 145.204
• InChiKey: LLLAUEJCYCBLPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(2-乙基苯基)乙腈 在 sodium hydride 作用下， 以 乙二醇乙醚 为溶剂， 反应 1.0h， 生成 1-[2-Amino-6-(2-ethylphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9
• 作为产物：
  描述：

  2-乙基苯胺 以 乙醇 为溶剂， 生成 2-(2-乙基苯基)乙腈
  参考文献：
  名称：

  van Zanten,B.; Nauta,W., Recueil des Travaux Chimiques des Pays-Bas, 1960, vol. 79, p. 1211 - 1222

  摘要：

  DOI：

文献信息

• One‐Pot Preparation of C ₁ ‐Homologated Aliphatic Nitriles from Aldehydes through a Wittig Reaction under Metal‐Cyanide‐Free Conditions
  作者：Masatoshi Ezawa、Hideo Togo

  DOI：10.1002/ejoc.201700277

  日期：2017.4.26

  A one-pot protocol to obtain C1-homologated aliphatic nitriles was achieved by treating aromatic and aliphatic aldehydes with the (methoxymethyl)triphenylphosphonium ylide followed by hydrolysis of the resulting methyl vinyl ethers with pTsOH (Ts = para-toluenesulfonyl) and treatment with molecular iodine and aqueous ammonia under metal cyanide free conditions. Neopentyl-type nitriles, which could

  通过用（甲氧基甲基）三苯基鏻叶立德处理芳香族和脂肪族醛，然后用 pTsOH（Ts = 对甲苯磺酰基）水解所得甲基乙烯基醚并用分子碘处理，实现了获得 C1 同系脂肪腈的一锅法和氨水在无金属氰化物条件下。使用本方法成功地获得了新戊基型腈，这些方法不能通过将新戊醇转化为甲苯磺酸盐并用金属氰化物处理的常规方法获得。
• SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES
  申请人：CHROMOCELL CORPORATION

  公开号：US20160130239A1

  公开（公告）日：2016-05-12

  Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I′: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.

  本文提供了钠通道调节化合物，特别是公式I的NaV1.7调节化合物或公式I'的化合物：特别提供了用于制备、制备中使用的中间体、包含的药物组合物以及包含给予这些化合物的治疗方法的过程。特别提供了用于治疗疼痛和糖尿病的化合物。
• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• Substituted Pyrazalones
  申请人：Lee Wen-Cherng

  公开号：US20100056505A1

  公开（公告）日：2010-03-04

  The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.

  该发明涉及式(I)的化合物作为TGFβ家族类型I受体Alk5和/或AIk 4的拮抗剂，以及使用的组合物和方法。式(I)的化合物可用于预防和/或治疗纤维化（如肾脏纤维化、肺部纤维化和肝脏纤维化）、进展性癌症或其他需要降低TGFβ家族信号活性的疾病。
• [EN] 5-ARYL-3,9-DIAZASPIRO[5.5]UNDECAN-2-ONE COMPOUNDS<br/>[FR] COMPOSÉS 5-ARYL-3,9-DIAZASPIRO[5.5]UNDÉCAN-2-ONE
  申请人：BAYER AG

  公开号：WO2020048830A1

  公开（公告）日：2020-03-12

  The present invention covers 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (l-a): in which A, R1 and R2 are as defined herein, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, and compounds of general formula (l-c) and general formula (l-d): in which R1 and R2 are as defined herein, for the treatment and/or prophylaxis of diseases, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions.

  本发明涵盖了一般式(I)和一般式(l-a)的5-芳基-3,9-二氮杂螺[5.5]十一碳酮化合物：其中A，R1和R2如本文所定义，含有所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物的用途，以及一般式(l-c)和一般式(l-d)的化合物：其中R1和R2如本文所定义，用于治疗和/或预防疾病，含有所述化合物的药物组合物和组合物，以及利用所述化合物制造药物组合物的用途。